Genmab A/S

Genmab A/S R&D Expenses

The Research & Development Expenses of Genmab A/S (GMAB.CO) as of Nov 17, 2026 is 1.61 B USD. In the previous year, Research & Development Expenses was 1.45 B USD — a change of 10.83% (higher).

R&D Expenses

1.61 BUSD

YoY

10.83%

Last updated:

Research & Development Expenses of Genmab A/S is 2025 1.61 B USD. Research & Development Expenses of Genmab A/S was 2024 1.45 B USD. It decreases by 10.83% higher compared to the previous year.

The Genmab A/S R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
212.74 M USD
Jan 1, 2019
354.68 M USD
Jan 1, 2020
466.32 M USD
Jan 1, 2021
621.51 M USD
Jan 1, 2022
826.79 M USD
Jan 1, 2023
1.13 B USD
Jan 1, 2024
1.45 B USD
Jan 1, 2025
1.61 B USD
The Genmab A/S R&D Expenses history
YEARR&D ExpensesYoY
1.61 BUSD+10.83%
1.45 BUSD+27.76%
1.13 BUSD+37.18%
826.79 MUSD+33.03%
621.51 MUSD+33.28%
466.32 MUSD+31.48%
354.68 MUSD+66.72%
212.74 MUSD+63.70%
129.96 MUSD+32.29%
98.24 MUSD+35.52%
72.49 MUSD-3.56%
75.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Research & Development Expenses of Genmab A/S is 1.61 B USD in 2025.

Research & Development Expenses of Genmab A/S changed from 1.45 B USD to 1.61 B USD, representing a 10.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Genmab A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genmab A/S

All Key Metrics — Genmab A/S